| Overview |
| bs-10727R-Cy3 |
| CD101 Polyclonal Antibody , Cy3 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD101 |
| 51-150/1021 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9398 |
| Q93033 |
| Cell membrane |
| V7; IGSF2; EWI-101; Immunoglobulin superfamily member 2; Cell surface glycoprotein V7; Glu-Trp-Ile EWI motif-containing protein 101; CD101; EWI101 |
| Plays a role as inhibitor of T-cells proliferation induced by CD3. Inhibits expression of IL2RA on activated T-cells and secretion of IL2. Inhibits tyrosine kinases that are required for IL2 production and cellular proliferation. Inhibits phospholipase C-gamma-1/PLCG1 phosphorylation and subsequent CD3-induced changes in intracellular free calcium. Prevents nuclear translocation of nuclear factor of activated T-cell to the nucleus. Plays a role in the inhibition of T-cell proliferation via IL10 secretion by cutaneous dendritic cells. May be a marker of CD4(+) CD56(+) leukemic tumor cells. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz